2025 Q3 -tulosraportti
97 päivää sitten1 t 0 min
Tarjoustasot
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
23,62VWAP
Alin
21,12VaihtoMäärä
498,1 37 054 130
VWAP
Ylin
23,62Alin
21,12VaihtoMäärä
498,1 37 054 130
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 23.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 3.11.2025 | |
| 2025 Q2 -tulosraportti | 4.8.2025 | |
| Vuosittainen yhtiökokous 2025 | 12.6.2025 | |
| 2025 Q1 -tulosraportti | 5.5.2025 | |
| 2024 Q4 -tulosraportti | 24.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·9 t sitten · MuokattuAmerican company drops Wegovy copy after two days: 'A really good piece of news for Novo Nordisk! https://www.dr.dk/nyheder/penge/amerikansk-firma-dropper-wegovy-kopi-efter-dage-en-rigtig-god-nyhed-novo-nordisk The stock plunges into the abyss tomorrow.
·7 t sittenIf it just does. Then I would like to buy them. Thanks in advance to those who sell at these prices.
·18 t sitten · MuokattuExcuse me, but why would one rather be invested in HIMS than NOVO? They are pretty much destroying all the strong fundamental characteristics the company could have had, by selling direct copies of competitors' medicine. That makes no sense. Why can't they just invest some of their capital in research and try to develop something themselves? I HOPE HIMS GOES BANKRUPT AND GOES DOWN IN DEATH!
·9 t sittenRegarding the question of why some would choose to invest in HIMS over NOVO, they are two very different companies. it's not just pharma, it's a digital health platform. Platform vs. Product (Direct customer contact) Where Novo relies on wholesalers, pharmacies, and insurance companies, Hims owns the entire customer journey directly (DTC – Direct-to-Consumer). They have over 2 million subscribers to whom they can 'sell' new solutions for everything from hair loss and mental health to weight loss and skincare. Asymmetric potential: Novo is a giant, and it takes enormous amounts to move the stock price. Hims is growing by 40-50 % (and recently topped 80 %). Since Hims is still a relatively small player, the mathematical potential for a '10-doubler' is much greater here. One is buying into a hyper-growth company that has just become profitable, which historically is a very strong time to enter. Personalized medicine Hims' biggest ace up its sleeve is their focus on personalized treatments. By blending medication (e.g., weight loss medication combined with vitamins or other preparations that reduce side effects), they create a product that Novo cannot deliver on a large scale. This makes them less vulnerable to generic competition because the customer buys a tailored solution and not just a standard pill. Price and availability (Market disruption) While Novo's Wegovy is expensive and often requires insurance, Hims targets the enormous 'out-of-pocket' market (as far as I know, they do not accept insurance money at all). They democratize access to medicine for the millions of Americans not covered by insurance. More than just an obesity stock - The acquisition of SMC Health (The Peptide Factory): A 503B facility is an "outsourcing pharmacy" that is allowed to produce medication in large batches. By owning this factory, Hims can produce their own peptides and customized medication blends. This makes them independent of external suppliers, significantly increases their profit margins, and ensures they do not run out of stock when demand rises. Development of proprietary "Pain-Free" injection systems: Hims invests in technology for their own delivery systems (autoinjectors). The goal is to make needles so small and the process so automated that it is practically painless. "Med Match" (AI-driven personalization): A proprietary AI platform that uses anonymized data from millions of patient interactions to help doctors find the exact precise dose and medication combination for the individual user. Heart Health (Combination Pills / "Hard Pills"): Hims has started combining different types of medication into one pill. They have launched products that combine ingredients for erectile dysfunction (ED) with, for example, statins (for high cholesterol). - The acquisition of Apostrophe (Dermatology): Although it's been a couple of years, the integration of Apostrophe is now complete. acquisition of a digital skincare platform with its own pharmacy. Expansion of Hers (Mental Health and Hair Loss): Hims (for men) started it all, but Hers (for women) is growing explosively right now. Massive investments in personalized treatment for female hair loss and mental health (for anxiety and depression).
·19 t sittenDo you think the stock will fall more than 10 % on Monday, and how much do you think NOVO will rise after the announcement that glp1 medicib may no longer be sold without FDA approval?- ·20 t sittenKåre S is left somewhat exposed. Good to see the FDA has woken up.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
97 päivää sitten1 t 0 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·9 t sitten · MuokattuAmerican company drops Wegovy copy after two days: 'A really good piece of news for Novo Nordisk! https://www.dr.dk/nyheder/penge/amerikansk-firma-dropper-wegovy-kopi-efter-dage-en-rigtig-god-nyhed-novo-nordisk The stock plunges into the abyss tomorrow.·7 t sittenIf it just does. Then I would like to buy them. Thanks in advance to those who sell at these prices.
- ·18 t sitten · MuokattuExcuse me, but why would one rather be invested in HIMS than NOVO? They are pretty much destroying all the strong fundamental characteristics the company could have had, by selling direct copies of competitors' medicine. That makes no sense. Why can't they just invest some of their capital in research and try to develop something themselves? I HOPE HIMS GOES BANKRUPT AND GOES DOWN IN DEATH!·9 t sittenRegarding the question of why some would choose to invest in HIMS over NOVO, they are two very different companies. it's not just pharma, it's a digital health platform. Platform vs. Product (Direct customer contact) Where Novo relies on wholesalers, pharmacies, and insurance companies, Hims owns the entire customer journey directly (DTC – Direct-to-Consumer). They have over 2 million subscribers to whom they can 'sell' new solutions for everything from hair loss and mental health to weight loss and skincare. Asymmetric potential: Novo is a giant, and it takes enormous amounts to move the stock price. Hims is growing by 40-50 % (and recently topped 80 %). Since Hims is still a relatively small player, the mathematical potential for a '10-doubler' is much greater here. One is buying into a hyper-growth company that has just become profitable, which historically is a very strong time to enter. Personalized medicine Hims' biggest ace up its sleeve is their focus on personalized treatments. By blending medication (e.g., weight loss medication combined with vitamins or other preparations that reduce side effects), they create a product that Novo cannot deliver on a large scale. This makes them less vulnerable to generic competition because the customer buys a tailored solution and not just a standard pill. Price and availability (Market disruption) While Novo's Wegovy is expensive and often requires insurance, Hims targets the enormous 'out-of-pocket' market (as far as I know, they do not accept insurance money at all). They democratize access to medicine for the millions of Americans not covered by insurance. More than just an obesity stock - The acquisition of SMC Health (The Peptide Factory): A 503B facility is an "outsourcing pharmacy" that is allowed to produce medication in large batches. By owning this factory, Hims can produce their own peptides and customized medication blends. This makes them independent of external suppliers, significantly increases their profit margins, and ensures they do not run out of stock when demand rises. Development of proprietary "Pain-Free" injection systems: Hims invests in technology for their own delivery systems (autoinjectors). The goal is to make needles so small and the process so automated that it is practically painless. "Med Match" (AI-driven personalization): A proprietary AI platform that uses anonymized data from millions of patient interactions to help doctors find the exact precise dose and medication combination for the individual user. Heart Health (Combination Pills / "Hard Pills"): Hims has started combining different types of medication into one pill. They have launched products that combine ingredients for erectile dysfunction (ED) with, for example, statins (for high cholesterol). - The acquisition of Apostrophe (Dermatology): Although it's been a couple of years, the integration of Apostrophe is now complete. acquisition of a digital skincare platform with its own pharmacy. Expansion of Hers (Mental Health and Hair Loss): Hims (for men) started it all, but Hers (for women) is growing explosively right now. Massive investments in personalized treatment for female hair loss and mental health (for anxiety and depression).
- ·19 t sittenDo you think the stock will fall more than 10 % on Monday, and how much do you think NOVO will rise after the announcement that glp1 medicib may no longer be sold without FDA approval?
- ·20 t sittenKåre S is left somewhat exposed. Good to see the FDA has woken up.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
23,62VWAP
Alin
21,12VaihtoMäärä
498,1 37 054 130
VWAP
Ylin
23,62Alin
21,12VaihtoMäärä
498,1 37 054 130
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 23.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 3.11.2025 | |
| 2025 Q2 -tulosraportti | 4.8.2025 | |
| Vuosittainen yhtiökokous 2025 | 12.6.2025 | |
| 2025 Q1 -tulosraportti | 5.5.2025 | |
| 2024 Q4 -tulosraportti | 24.2.2025 |
2025 Q3 -tulosraportti
97 päivää sitten1 t 0 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 23.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 3.11.2025 | |
| 2025 Q2 -tulosraportti | 4.8.2025 | |
| Vuosittainen yhtiökokous 2025 | 12.6.2025 | |
| 2025 Q1 -tulosraportti | 5.5.2025 | |
| 2024 Q4 -tulosraportti | 24.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·9 t sitten · MuokattuAmerican company drops Wegovy copy after two days: 'A really good piece of news for Novo Nordisk! https://www.dr.dk/nyheder/penge/amerikansk-firma-dropper-wegovy-kopi-efter-dage-en-rigtig-god-nyhed-novo-nordisk The stock plunges into the abyss tomorrow.·7 t sittenIf it just does. Then I would like to buy them. Thanks in advance to those who sell at these prices.
- ·18 t sitten · MuokattuExcuse me, but why would one rather be invested in HIMS than NOVO? They are pretty much destroying all the strong fundamental characteristics the company could have had, by selling direct copies of competitors' medicine. That makes no sense. Why can't they just invest some of their capital in research and try to develop something themselves? I HOPE HIMS GOES BANKRUPT AND GOES DOWN IN DEATH!·9 t sittenRegarding the question of why some would choose to invest in HIMS over NOVO, they are two very different companies. it's not just pharma, it's a digital health platform. Platform vs. Product (Direct customer contact) Where Novo relies on wholesalers, pharmacies, and insurance companies, Hims owns the entire customer journey directly (DTC – Direct-to-Consumer). They have over 2 million subscribers to whom they can 'sell' new solutions for everything from hair loss and mental health to weight loss and skincare. Asymmetric potential: Novo is a giant, and it takes enormous amounts to move the stock price. Hims is growing by 40-50 % (and recently topped 80 %). Since Hims is still a relatively small player, the mathematical potential for a '10-doubler' is much greater here. One is buying into a hyper-growth company that has just become profitable, which historically is a very strong time to enter. Personalized medicine Hims' biggest ace up its sleeve is their focus on personalized treatments. By blending medication (e.g., weight loss medication combined with vitamins or other preparations that reduce side effects), they create a product that Novo cannot deliver on a large scale. This makes them less vulnerable to generic competition because the customer buys a tailored solution and not just a standard pill. Price and availability (Market disruption) While Novo's Wegovy is expensive and often requires insurance, Hims targets the enormous 'out-of-pocket' market (as far as I know, they do not accept insurance money at all). They democratize access to medicine for the millions of Americans not covered by insurance. More than just an obesity stock - The acquisition of SMC Health (The Peptide Factory): A 503B facility is an "outsourcing pharmacy" that is allowed to produce medication in large batches. By owning this factory, Hims can produce their own peptides and customized medication blends. This makes them independent of external suppliers, significantly increases their profit margins, and ensures they do not run out of stock when demand rises. Development of proprietary "Pain-Free" injection systems: Hims invests in technology for their own delivery systems (autoinjectors). The goal is to make needles so small and the process so automated that it is practically painless. "Med Match" (AI-driven personalization): A proprietary AI platform that uses anonymized data from millions of patient interactions to help doctors find the exact precise dose and medication combination for the individual user. Heart Health (Combination Pills / "Hard Pills"): Hims has started combining different types of medication into one pill. They have launched products that combine ingredients for erectile dysfunction (ED) with, for example, statins (for high cholesterol). - The acquisition of Apostrophe (Dermatology): Although it's been a couple of years, the integration of Apostrophe is now complete. acquisition of a digital skincare platform with its own pharmacy. Expansion of Hers (Mental Health and Hair Loss): Hims (for men) started it all, but Hers (for women) is growing explosively right now. Massive investments in personalized treatment for female hair loss and mental health (for anxiety and depression).
- ·19 t sittenDo you think the stock will fall more than 10 % on Monday, and how much do you think NOVO will rise after the announcement that glp1 medicib may no longer be sold without FDA approval?
- ·20 t sittenKåre S is left somewhat exposed. Good to see the FDA has woken up.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
23,62VWAP
Alin
21,12VaihtoMäärä
498,1 37 054 130
VWAP
Ylin
23,62Alin
21,12VaihtoMäärä
498,1 37 054 130
Välittäjätilasto
Dataa ei löytynyt